Similarly as in a previous study, isoliquiritigenin was found to significantly inhibit VEGF expression in breast cancer cells via promoting HIF-1α proteasome degradation, and directly interacted with VEGFR-2 to block its kinase activity. This evidence concerns the gene VEGFA and breast cancer.